Evaluation of endocrine therapy of prostate cancer by assessing tumor markers and hormone parameters. Hormonal "cross-over" treatment of false endocrine independent tumors.
作者信息
Kraljić I, Tarle M
机构信息
Clinic of Urology, Clinical Hospital Dr M. Stojanović, Zagreb, Croatia, Yugoslavia.
出版信息
Prog Clin Biol Res. 1987;243B:521-5.
PMID:3659050
Abstract
摘要
相似文献
1
2
Endocrine therapy in the management of advanced prostatic cancer: the case for early initiation of treatment.
Urol Clin North Am. 1980 Oct;7(3):639-43.
3
[Current value of hormonotherapy in cancer of the prostate].[激素疗法在前列腺癌治疗中的当前价值]
Minerva Urol Nefrol. 1984 Oct-Dec;36(4):329-35.
4
Monitoring of prostate volume by ultrasound in hormonally treated prostate cancer.激素治疗的前列腺癌患者前列腺体积的超声监测
Prog Clin Biol Res. 1987;243B:13-9.
5
The case for early combined hormonal and cytostatic treatment for metastatic prostatic carcinoma.转移性前列腺癌早期联合激素与细胞抑制治疗的病例分析
Prog Clin Biol Res. 1987;243B:449-53.
6
The questionable use of hormone therapy in advanced carcinoma of the prostate.激素疗法在晚期前列腺癌中的可疑应用。
Urol Clin North Am. 1980 Oct;7(3):631-8.
7
Deferred hormone treatment in prostate cancer.前列腺癌的延迟激素治疗
Prog Clin Biol Res. 1987;243B:439-40.
8
Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.使用替代生物标志物预测去势抵抗性前列腺癌男性患者的临床获益：文献更新与综述
Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14.
9
[Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer].[前列腺特异性抗原的动态变化作为前列腺癌内分泌治疗的预后因素]
Hinyokika Kiyo. 1999 Jan;45(1):31-5.
Zotero 插件